• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

6.835 -1.145 (-14.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,108,955
Open 7.660
Bid (Size) 6.760 (1,500)
Ask (Size) 6.800 (400)
Prev. Close 7.980
Today's Range 6.830 - 7.820
52wk Range 2.960 - 40.37
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Capricor (CAPR) Q2 2026 Earnings Call Transcript ↗
August 20, 2026
Deramiocel faces regulatory headwinds; management pursues upper limb indication. 
Via The Motley Fool
Topics Earnings
News headline image
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights
August 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit

Performance

YTD
-75.9%
-75.9%
1 Month
-65.5%
-65.5%
3 Month
-76.9%
-76.9%
6 Month
-76.6%
-76.6%
1 Year
-4.7%
-4.7%

More News

Read More
News headline image
Kaplan Fox Alerts Investors to an Upcoming Deadline of September 28, 2026 in the Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action
August 20, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
August 20, 2026
From SkyMedia, LLC
Via GlobeNewswire
News headline image
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026
August 20, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
August 20, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026
August 19, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
August 19, 2026
Via Newsfile
Topics Lawsuit
News headline image
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
August 19, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit: Investors Face September 28, 2026, Deadline
August 19, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
August 18, 2026
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.
August 18, 2026
From Robbins LLP
Via Business Wire
News headline image
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
August 18, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026
August 18, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPR
August 18, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
August 18, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Kaplan Fox Class Action Reminder: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Lead Plaintiff Deadline is September 28, 2026
August 18, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
August 18, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) is September 28, 2026
August 17, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
August 17, 2026
Via Newsfile
Topics Lawsuit
News headline image
Kaplan Fox Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Act Before the Lead Plaintiff Deadline on September 28, 2026
August 17, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit Seeks Recovery for Investors; September 28, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
August 17, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
August 16, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPR
August 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role
August 14, 2026
Via NewMediaWire
Topics Lawsuit

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 6.835
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 08/20/26 04:00 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 312.44M
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 312M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap